TABLE 1.
Percent reductions in Lp(a) at parent study week 12 by baseline Lp(a), statin use, and achieved LDL-C when LDL-C was uncorrected and corrected for Lp(a)-C
| Reduction in Lp(a) at Week 12 (%) | |||
| Statin at Baseline | No Statin at Baseline | ||
| Lp(a) at Baseline | LDL-C ≤40 mg/dl at Week 12 | LDL-C >70 mg/dl at Week 12 | LDL-C >70 mg/dl at Week 12a |
| LDL-C uncorrected for Lp(a)-C | |||
| <75 nmol/l | |||
| N | 393 | 98 | 126 |
| Median (Q1, Q3) | −28.6 (−50.0, 0.0) | −16.7 (−34.6, 0.0) | −22.9 (−38.9, 0.0) |
| 75–125 nmol/l | |||
| N | 27 | 24 | 17 |
| Median (Q1, Q3) | −28.2 (−46.9, −20.9) | −16.6 (−28.4, 0.5) | −26.3 (−33.7, −18.0) |
| >125 nmol/l | |||
| N | 109 | 82 | 47 |
| Median (Q1, Q3) | −25.7 (−34.0, −15.1) | −12.8 (−26.0, −3.3) | −15.5 (−23.7, −3.3) |
| Overall | |||
| N | 1,178 | 432 | |
| Median (Q1, Q3) | −23.3 (−40.0, −5.3) | −21.8 (−39.7, 0.0) | |
| <75 nmol/l | |||
| N | 718 | 309 | |
| Median (Q1, Q3) | −28.1 (−46.7, 0.0) | −23.3 (−44.4, 0.0) | |
| 75–125 nmol/l | |||
| N | 81 | 45 | |
| Median (Q1, Q3) | −26.4 (−40.2, −11.8) | −27.7 (−35.5, −17.5) | |
| >125 nmol/l | |||
| N | 379 | 78 | |
| Median (Q1, Q3) | −18.1 (−29.4, −7.1) | −16.5 (−25.0, −4.6) | |
| LDL-C corrected for Lp(a)-C | |||
| <75 nmol/l | |||
| N | 419 | 91 | 114 |
| Median (Q1, Q3) | −28.6 (−50.0, 0.0) | −16.7 (−36.7, 0.0) | −21.7 (−38.5, 0.0) |
| 75–125 nmol/l | |||
| N | 44 | 19 | 14 |
| Median (Q1, Q3) | −27.1 (−43.6, −12.2) | −12.0 (−20.3, 4.2) | −22.7 (−30.1, −13.0) |
| >125 nmol/l | |||
| N | 274 | 27 | 24 |
| Median (Q1, Q3) | −18.6 (−29.7, −7.0) | −16.8 (−26.4, −7.1) | −17.9 (−26.9, −6.3) |
a
There were too few patients to analyze in the ≤40 mg/dl group not taking a statin at baseline.